Here Are Some Essential Facts About Alexandria Real Estate Equities

By Harris Dyer • Monday, November 18 10:18 • Permanent Link

Join us for a quick overview of Alexandria Real Estate Equities, a Specialty Real Estate Investment Trust company whose shares moved -1.4% today. Here are some facts about the stock that should help you see the bigger picture:

Alexandria Real Estate Equities has moved 1.1% over the last year, and the S&P 500 logged a change of 29.1%
ARE has an average analyst rating of buy and is -19.42% away from its mean target price of $129.23 per share
Its trailing earnings per share (EPS) is $1.64
Alexandria Real Estate Equities has a trailing 12 month Price to Earnings (P/E) ratio of 63.5 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $3.44 and its forward P/E ratio is 30.3
The company has a Price to Book (P/B) ratio of 0.98 in contrast to the S&P 500's average ratio of 4.74
Alexandria Real Estate Equities is part of the Real Estate sector, which has an average P/E ratio of 31.12 and an average P/B of 2.15
ARE has reported YOY quarterly earnings growth of 648.4% and gross profit margins of 0.7%
The company has a free cash flow of $1.37 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche since our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. Alexandria has a total market capitalization of $34.4 billion and an asset base in North America of 74.1 million SF as of March 31, 2024, which includes 42.2 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction and one committed near-term project expected to commence construction in the next two years, 2.5 million RSF of priority anticipated development and redevelopment projects, and 24.1 million SF of future development projects. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.